title: [Zoledronic acid (zoledronate) in children with osteogenesis imperfecta].
abstract: BACKGROUND
  Zoledronic acid or zo/edronate is a potent bisphosphonate that recently has been used in children with osteoporosis and osteogenesis imperfecta (01), so it could be an option in the treatment of children with this terrible disease that virtually condemns them to a life of pain and prostration. The aim of this study was to evaluate the clinical and biochemical conditions of pediatric patients with 01 before and after treatment with zo /edronate.
  
  
  RESULTS
  We included 14 patients, median age six years (6 months to 14 years), eight (57.1 %) males and six (42 .9%) females, weight 19 kg (5.8-45 kg). According to the type of 01, six (42.9%) were type I, six (42.9%) type Ill, and two (14.2%) type IV The functional score (Bleck) previous to treatment was 4 (1-9) and 6 (2-9) after treatment (p = 0.001). Pain intensity prior to zo/edronate was 2 (1-9) and 0 (0-2) after (p = 0.008). Previous fractures five (1-15) and post-treatment one (0-2) (p = 0.001 ). There were no significant differences in calcium, phosphorus, alkaline phosphatase, and parathyroid hormone.
  
  
  CONCLUSIONS
  Zoledronic acid decreases the number of bone fractures and pain in children with osteogenesis imperfect and improves functional status. The most common side effects were fever and bone pain within five days after the infusion,which disappear paracetamol. No adverse long-term effects such as hypocalcemia or hypoparathyroidism were reported.
authors.affiliation: Servicio de Pediatría, Unidad Médica de Alta Especialidad (UMAE) N.o 25, Centro Médico Nacional del Noreste, Monterrey, N.L., Mexico.
authors.forename: Luz María
authors.initials: LM
authors.lastname: Sánchez-Sánchez
authors.affiliation: Servicio de Pediatría, Unidad Médica de Alta Especialidad (UMAE) N.o 25, Centro Médico Nacional del Noreste, Monterrey, N.L., Mexico.
authors.forename: Alfredo Uriel
authors.initials: AU
authors.lastname: Cabrera-Pedroza
authors.affiliation: Servicio de Pediatría, Unidad Médica de Alta Especialidad (UMAE) N.o 25, Centro Médico Nacional del Noreste, Monterrey, N.L., Mexico.
authors.forename: Gerardo
authors.initials: G
authors.lastname: Palacios-Saucedo
authors.affiliation: Servicio de Pediatría, Unidad Médica de Alta Especialidad (UMAE) N.o 25, Centro Médico Nacional del Noreste, Monterrey, N.L., Mexico.
authors.forename: Beatriz
authors.initials: B
authors.lastname: de la Fuente-Cortez
mesh_terms: D000293:Adolescent; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007223:Infant; D008297:Male; D010013:Osteogenesis Imperfecta / Q000175:diagnosis / Q000188:drug therapy*; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid